Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GIMEMA ALL 0394

 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (4)

Antineoplastic Combined Chemotherapy ProtocolsCytarabineEtoposideIdarubicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two…
Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2019
2019
Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes.
Most patients affected by Myelodysplastic syndromes (MDS) develop transfusion dependence, which can be correlated with poorer… Expand
Is this relevant?
2018
2018
Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3…
Introduction: The phase 3 GIMEMA-MMY-3006 trial comparing bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide… Expand
Is this relevant?
2015
2015
Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients
Introduction: Several studies demonstrated that continuous therapy (CT) prolonged progression-free survival (PFS); conflicting… Expand
Is this relevant?
2015
2015
Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple…
Introduction The introduction of novel agents in the treatment of Multiple Myeloma (MM) led to a significant improvement in the… Expand
Is this relevant?
2015
2015
Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients
Introduction Several trials have shown that maintenance therapy prolongs progression-free survival (PFS) in multiple myeloma (MM… Expand
Is this relevant?
2014
2014
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2014
2014
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.
Multiple myeloma is a plasma cell disorder characterized by malignant plasma cell infiltration in the bone marrow, serum and/or… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
2013
2013
Absolute monocyte count at diagnosis and survival in mantle cell lymphoma.
Chaperot, L., Bendriss, N., Manches, O., Gressin, R., Maynadie, M., Trimoreau, F., Orfeuvre, H., Corront, B., Feuillard, J… Expand
  • table I
  • figure 1
Is this relevant?
Highly Cited
2005
Highly Cited
2005
GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children.
The role of all-trans retinoic acid (ATRA) in pediatric acute promyelocytic leukemia (APL) is the topic of several ongoing… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE